Aurinia Pharmaceuticals (AUPH) Equity Ratio (2019 - 2026)

Aurinia Pharmaceuticals has reported Equity Ratio for 8 years, with the latest figure at 0.78 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 13.03% year-over-year to 0.78; the trailing twelve-month figure through Mar 2026 stood at 0.78 (up 13.03% YoY), and the FY2025 full-year result was 0.77, up 12.83% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.78, up from 0.77 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q1 2022, with the low at 0.67 in Q2 2025.
• Historically, Equity Ratio has averaged 0.76 across 5 years, with a median of 0.71 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio dropped 19.91% — and 2026, when it grew 13.03%.
• Aurinia Pharmaceuticals' Equity Ratio stood at 0.86 in 2022, then retreated by 19.91% to 0.69 in 2023, then fell by 0.59% to 0.69 in 2024, then increased by 12.83% to 0.77 in 2025, then climbed by 1.36% to 0.78 in 2026.
• The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.77 (Q4 2025), and 0.69 (Q3 2025), per Business Quant data.